Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 78, Issue 5, Pages 496-512Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2021.03.346
Keywords
genetics; precision medicine; type 2 diabetes
Categories
Funding
- National Institutes of Health [SNPG9895, F31 MH101905]
- American Heart Association [AHA 16POST27250048]
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [U01-DK105535, U01-DK085545, UM1DK126185]
- Stanford Diabetes Research Center (NIDDK) [P30DK116074]
- NIDDK [1R01DK107437, 1R01 DK116750, 1R01DK106236]
- American Diabetes Association [1-19-JDF-108]
- Pilot and Feasibility Grant
- American Heart Association
- Wellcome [095101, 200837]
Ask authors/readers for more resources
Type 2 diabetes is highly prevalent and contributes to cardiovascular disease. Despite significant progress in identifying genetic variation associated with T2D risk, the promise of precision medicine has not been fully realized. Recent studies have identified sub-groups of individuals with differential risk for intermediate phenotypes, which could aid in patient stratification and bridging the gap towards precision medicine for T2D.
Type 2 diabetes (T2D) is highly prevalent and is a strong contributor for cardiovascular disease. However, there is significant heterogeneity in disease pathogenesis and the risk of complications. Enormous progress has been made in our ability to catalog genetic variation associated with T2D risk and variation in disease-relevant quantitative traits. These discoveries hold the potential to shed light on tractable targets and pathways for safe and effective therapeutic development, but the promise of precision medicine has been slow to be realized. Recent studies have identified sub-groups of individuals with differential risk for intermediate phenotypes (eg, lipid levels, fasting insulin, body mass index) that contribute to T2D risk, helping to account for the observed clinical heterogeneity. These partitioned genetic risk scores not only have the potential to identify patients at greatest risk of cardiovascular disease and rapid disease progression, but also could aid patient stratification bridging the gap toward precision medicine for T2D. (C) 2021 by the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available